Last updated: October 6, 2026
Anaprox is a legacy prescription brand of naproxen sodium, an immediate-release nonsteroidal anti-inflammatory drug. Its commercial trajectory is defined by patent expiry, broad generic substitution, and competition from OTC naproxen products such as Aleve. The brand no longer has the characteristics of a high-value protected pharmaceutical asset: its active ingredient is mature, its core intellectual-property barriers have expired, and publicly reported revenue is not separately disclosed.
What is Anaprox and how is it positioned in the NSAID market?
Anaprox contains naproxen sodium, the sodium salt of naproxen. The product was marketed as prescription tablets in 275-mg and 550-mg strengths for pain, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, dysmenorrhea, and other inflammatory conditions. Naproxen sodium provides faster dissolution than naproxen free acid, although both products deliver the same active moiety after absorption.
| Attribute |
Anaprox |
| Active ingredient |
Naproxen sodium |
| Drug class |
NSAID |
| Dosage form |
Immediate-release oral tablet |
| Historical strengths |
275 mg and 550 mg |
| Regulatory status |
Legacy prescription product; generic naproxen sodium products remain available |
| Primary competitors |
Generic naproxen sodium, generic naproxen, ibuprofen, diclofenac, celecoxib, OTC Aleve |
| Originator company |
Syntex/Roche commercial lineage |
| Current economic profile |
Mature, largely genericized product |
The product competes in a crowded analgesic and anti-inflammatory market. Its clinical advantages are limited to the established efficacy, relatively long half-life, and familiar dosing profile of naproxen. Its principal disadvantages are class-wide NSAID risks, including gastrointestinal bleeding, renal toxicity, fluid retention, hypertension, and cardiovascular events. The FDA label contains boxed warnings for serious cardiovascular and gastrointestinal adverse events. (U.S. Food and Drug Administration [FDA], n.d.-a)
When did Anaprox lose exclusivity?
Anaprox lost meaningful market exclusivity decades ago. The relevant exclusivity event was the expiration of patents covering naproxen and related formulations, not a recent loss of regulatory exclusivity.
Naproxen was developed by Syntex and commercialized before the modern Hatch-Waxman framework became the principal mechanism for generic competition. The foundational compound and early product patents expired long before the current market period. Generic naproxen and naproxen sodium products subsequently became widely available from multiple manufacturers.
| Exclusivity layer |
Anaprox position |
| Foundational compound protection |
Expired |
| Early formulation protection |
Expired |
| New chemical entity exclusivity |
Not relevant to the current market |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not applicable |
| Current regulatory exclusivity |
None of material commercial importance |
| Generic substitution |
Broad and established |
The commercial consequence was a shift from originator pricing to commodity pricing. Once multiple manufacturers could supply equivalent naproxen sodium tablets, pharmacies and payers had little reason to maintain a premium for Anaprox.
What patents protect Anaprox?
No unexpired patent estate appears to protect the historical Anaprox immediate-release tablet as a commercially meaningful product in the United States.
The relevant intellectual-property categories were:
- Patents covering naproxen as a chemical compound.
- Patents covering naproxen sodium or salt forms.
- Formulation and tablet-composition patents.
- Manufacturing-process patents.
- Labeling and method-of-use rights.
The original compound and salt-form barriers have expired. Any later formulation or process patents would need to claim a distinct formulation or manufacturing process, rather than the ordinary immediate-release tablet, to create a meaningful barrier. Generic manufacturers have supplied standard naproxen sodium tablets for many years, indicating that no broad enforceable patent barrier blocks conventional production.
How strong is the Anaprox patent estate?
The current patent estate is weak for commercial purposes.
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Formulation protection |
No material current barrier identified for standard immediate-release tablets |
| Method-of-use protection |
Limited practical value because core indications are longstanding |
| Manufacturing protection |
Potentially relevant to specific processes, but not a broad market barrier |
| Patent litigation leverage |
Low |
| Generic blocking power |
None of material significance |
| Lifecycle-management value |
Low |
A patent covering a narrow manufacturing step would not normally prevent competitors from supplying naproxen sodium if they can use an alternative process. Similarly, a narrow method-of-use patent would have limited value where physicians prescribe the drug for established NSAID indications and generic substitution is routine.
What is the Orange Book status of Anaprox?
The FDA Orange Book is the principal U.S. reference for approved drug products, therapeutic-equivalence ratings, and listed patents for applicable prescription products. The historical Anaprox NDA is associated with naproxen sodium tablets, but the brand is not the principal source of current U.S. market supply. FDA-approved generic products have the commercial role that Anaprox once occupied. (FDA, n.d.-b)
The relevant market characteristics are:
- Standard naproxen sodium tablets are supplied by multiple generic manufacturers.
- Therapeutic-equivalence ratings support substitution where the applicable generic product has an “AB” rating.
- There is no current Orange Book patent listing that creates a significant barrier around the ordinary Anaprox tablet market.
- OTC naproxen products operate through separate labeling and distribution channels, even though they contain the same active ingredient.
The absence of a live, commercially meaningful patent listing is more important than the historical presence of the Anaprox NDA. An approved NDA can remain a regulatory record after the corresponding brand has lost commercial relevance.
What formulation patents protect Anaprox?
Anaprox was an immediate-release tablet rather than a protected extended-release delivery system, transdermal product, implant, or complex drug-device combination.
Potential formulation distinctions include:
- Naproxen free acid versus naproxen sodium.
- 275-mg versus 550-mg tablet strengths.
- Immediate-release tablet excipient systems.
- Enteric-coated or delayed-release products.
- Suspension and liquid formulations.
- Extended-release naproxen products.
These distinctions do not create a durable Anaprox-specific moat. Generic manufacturers can market the standard immediate-release strengths, while other manufacturers can compete through different dosage forms. The main technical requirement is control of dissolution, assay, stability, content uniformity, and bioequivalence.
Are there method-of-use patents for Anaprox?
Method-of-use protection has little current commercial value for Anaprox. The product’s historical indications involve common inflammatory and pain conditions, including osteoarthritis, rheumatoid arthritis, dysmenorrhea, and acute pain. These uses are longstanding and are not dependent on a recent proprietary mechanism or biomarker-defined population.
A method-of-use patent would face several practical limitations:
- The underlying indications are clinically established.
- Generic labels can rely on approved labeling and applicable regulatory pathways.
- Physicians can prescribe generic naproxen sodium for the same conditions.
- Enforcement against routine prescribing would be difficult.
- Payer substitution reduces the value of brand-specific labeling.
Which companies compete with Anaprox?
Anaprox competes against three different groups: generic prescription manufacturers, OTC naproxen brands, and alternative NSAID products.
| Competitive group |
Examples |
Competitive basis |
| Generic naproxen sodium |
Teva, Sandoz, Amneal, Perrigo and other suppliers, depending on market |
Low price and pharmacy substitution |
| OTC naproxen |
Aleve and store-brand naproxen sodium |
Consumer recognition and retail availability |
| Other traditional NSAIDs |
Ibuprofen, diclofenac, meloxicam, indomethacin |
Price, dosing, physician familiarity |
| COX-2 selective NSAIDs |
Celecoxib |
Gastrointestinal and dosing considerations |
| Non-NSAID analgesics |
Acetaminophen and opioid products in selected settings |
Different safety and efficacy profiles |
The most direct competitive threat is generic naproxen sodium, not another branded prescription product. OTC Aleve also places a ceiling on the price that a prescription naproxen sodium brand can command.
How has the financial trajectory of Anaprox changed?
Anaprox’s financial trajectory follows the standard lifecycle of a mature small-molecule medicine.
Launch and brand expansion
During the originator period, Anaprox benefited from:
- Physician familiarity with naproxen.
- Prescription distribution.
- Differentiation through the sodium salt and tablet strengths.
- Broad use across pain and inflammatory disorders.
Revenue during this stage would have depended on branded prescription volume and price realization.
Patent expiry and generic entry
After core patent expiry, generic manufacturers entered the market. The economic effects were predictable:
- Rapid decline in branded prescription volume.
- Lower net price.
- Increased pharmacy substitution.
- Reduced sales-force return on investment.
- Loss of negotiating leverage with payers.
- Migration of demand toward generic and OTC products.
Mature generic market
The current economic model is based on volume, manufacturing efficiency, supply reliability, and contracting rather than brand equity. Generic suppliers compete on:
- Cost of active pharmaceutical ingredient.
- Tablet manufacturing scale.
- Regulatory compliance.
- Wholesaler and pharmacy contracts.
- Supply continuity.
- Ability to avoid recalls and shortages.
There is no publicly reported standalone Anaprox revenue stream in the major financial disclosures of the historical originator companies. Roche reports group and pharmaceutical performance at much broader levels, and mature products such as Anaprox are not separately itemized. Public market data therefore support a directional assessment rather than a precise annual revenue series.
| Period |
Revenue profile |
Main driver |
| Originator period |
Branded prescription revenue |
Clinical adoption and brand promotion |
| Early generic period |
Sharp decline |
Substitution and price compression |
| Mature generic period |
Low-margin residual value |
Manufacturing scale and contracts |
| Current market |
Limited standalone brand value |
Generic and OTC naproxen demand |
What revenue exposure does Anaprox create for manufacturers?
For the historical brand owner, Anaprox is unlikely to represent material current revenue exposure. The commercial risk is concentrated among generic manufacturers and suppliers of naproxen API rather than a single originator.
Revenue exposure can still arise from:
- Temporary generic supply shortages.
- API price changes.
- Regulatory manufacturing actions.
- Contract losses.
- Product recalls.
- Retail demand for naproxen sodium.
- Regional brand persistence outside the United States.
Because Anaprox is an old product, the principal value is operational. A manufacturer with a low-cost, reliable supply chain may earn acceptable returns despite low unit prices. A manufacturer with high overhead or weak manufacturing utilization is more vulnerable to margin erosion.
What is the FDA regulatory status of Anaprox?
The relevant U.S. regulatory framework is the approved prescription NSAID labeling for naproxen sodium and the abbreviated new drug application pathway for generic equivalents. The historical brand label includes the standard NSAID cardiovascular, gastrointestinal, renal, hepatic, and hypersensitivity warnings. (FDA, n.d.-a)
There is no FDA pathway advantage associated with Anaprox today. A new entrant would generally rely on:
- An ANDA for a generic equivalent.
- Demonstration of pharmaceutical equivalence.
- Bioequivalence data.
- Compliance with current good manufacturing practice.
- Approved labeling consistent with the reference product.
A 505(b)(2) pathway could be relevant for a materially different dosage form or formulation, but it would not restore exclusivity to the conventional Anaprox tablet.
Are there Paragraph IV challenges involving Anaprox?
Paragraph IV litigation is not a meaningful current risk category for the conventional Anaprox product. Paragraph IV certifications matter when an ANDA applicant challenges unexpired Orange Book patents. The core Anaprox patent barriers expired long ago, and generic naproxen sodium has already achieved broad market penetration.
The relevant litigation profile is therefore:
| Issue |
Current significance |
| New Paragraph IV challenge to Anaprox |
Low |
| Originator patent enforcement |
Low |
| Generic entry litigation |
Low |
| Labeling disputes |
Possible in theory, limited commercial effect |
| Product-liability litigation |
More relevant than patent litigation |
| Manufacturing and quality litigation |
Potentially relevant to suppliers |
What patent litigation affects Anaprox?
No current, material patent litigation is associated with the ordinary U.S. Anaprox immediate-release tablet in the cited regulatory record. The more relevant legal risks are product liability and regulatory compliance.
Potential non-patent exposure includes:
- NSAID gastrointestinal injury claims.
- Cardiovascular-event claims.
- Failure-to-warn allegations.
- Manufacturing-defect claims.
- Product recalls.
- Distribution-chain compliance issues.
These risks affect all naproxen suppliers and are not unique to Anaprox.
Are there licensing deals involving Anaprox?
Anaprox’s historical commercial development reflects the Syntex and Roche corporate lineage rather than a current licensing-driven asset. No material active licensing arrangement is publicly associated with the legacy Anaprox brand in the current generic market.
Licensing value would be limited because:
- The active ingredient is off patent.
- Numerous manufacturers can supply equivalent products.
- Regulatory approval does not confer meaningful exclusivity.
- OTC naproxen products reduce prescription-brand differentiation.
- The product has low switching costs for pharmacies and payers.
How does Anaprox compare with Aleve and generic naproxen?
| Factor |
Anaprox |
Generic naproxen sodium |
Aleve |
| Market channel |
Historical prescription brand |
Prescription and, in some markets, OTC |
OTC |
| Active ingredient |
Naproxen sodium |
Naproxen sodium |
Naproxen sodium |
| Brand premium |
Low or absent |
None or minimal |
Consumer brand premium |
| Patent protection |
Expired |
No meaningful barrier |
Brand and trade-mark protection, not active-ingredient exclusivity |
| Prescriber influence |
Historical |
Limited because of substitution |
Limited; consumer-driven |
| Pricing power |
Very low |
Low |
Higher than commodity generic in retail |
| Main commercial asset |
Legacy recognition |
Low-cost supply |
Retail distribution and brand recognition |
Aleve’s commercial position is stronger than Anaprox’s because Aleve operates as a consumer brand. That advantage is marketing-based rather than a result of active-ingredient patent protection.
What generic launch scenarios exist for Anaprox?
A new generic entrant would face low legal barriers but substantial commercial competition. The main launch scenarios are:
- Commodity prescription launch: Compete through low price and wholesaler access.
- Contract-manufacturing launch: Supply a private-label or pharmacy-brand product.
- OTC expansion: Pursue an OTC product, subject to applicable FDA requirements and labeling.
- Alternative dosage form: Develop a suspension, liquid, or modified-release product, with greater regulatory and formulation complexity.
- Regional launch: Enter markets where Anaprox retains residual brand recognition.
The most realistic scenario is a low-cost standard tablet launch. A premium branded relaunch would face weak pricing power and substantial substitution.
What manufacturing and IP barriers remain?
The principal barriers are operational rather than intellectual property-based.
Manufacturing barriers
- Reliable naproxen API sourcing.
- Compliance with FDA current good manufacturing practice.
- Control of tablet dissolution and content uniformity.
- Stable supply of excipients and packaging.
- Ability to meet price competition.
- Avoidance of facility observations, warning letters, and recalls.
Intellectual-property barriers
For the ordinary immediate-release tablet, meaningful barriers are limited. A company pursuing a differentiated product could seek protection for:
- A novel release profile.
- A new dosage form.
- A combination product.
- A specific manufacturing process.
- A distinct clinical use.
Those protections would apply to the improvement, not to Anaprox’s basic naproxen sodium product.
What is the geographic coverage of Anaprox?
The commercial status of the Anaprox name varies by jurisdiction. Trademark ownership, marketing rights, regulatory approvals, and product availability are country-specific. The U.S. market is dominated by generic prescription products and OTC naproxen, while the Anaprox name may retain residual recognition in selected non-U.S. markets.
Geographic value is therefore fragmented:
- U.S.: genericized and low brand value.
- Europe: country-specific generic and regulatory status.
- Canada and Australia: possible residual brand recognition, subject to local marketing status.
- Emerging markets: potential brand persistence, but lower pricing and variable regulatory controls.
A country-by-country trademark or regulatory review is required before assigning value to the Anaprox name outside the United States.
Key Takeaways
- Anaprox is a legacy naproxen sodium prescription brand with no material current exclusivity.
- The foundational compound and formulation protections expired decades ago.
- Generic naproxen sodium is the principal prescription competitor.
- OTC Aleve limits the pricing power of any prescription naproxen sodium brand.
- Current commercial value lies in manufacturing efficiency and supply reliability, not patent protection.
- Public company filings do not provide a separate current Anaprox revenue stream.
- Paragraph IV litigation and patent-based generic blocking are no longer significant issues.
- Product liability, quality compliance, API sourcing, and generic price competition are more relevant risks.
- A new standard-tablet entrant could obtain regulatory approval but would face a crowded, low-margin market.
- Any residual brand value is likely jurisdiction-specific and materially below the product’s originator-era value.
FAQs
Is Anaprox still sold in the United States?
Generic naproxen sodium products remain widely available, while the historical Anaprox brand has limited current commercial importance in the U.S. prescription market.
Is Anaprox the same as Aleve?
Both contain naproxen sodium, but Anaprox was marketed as a prescription product and Aleve is primarily an OTC consumer brand. Strengths, labeling, packaging, and distribution can differ.
Does Anaprox have a live U.S. patent?
No material unexpired patent barrier is associated with the conventional immediate-release Anaprox tablet.
Can a company launch a generic version of Anaprox?
Yes. A company can pursue an ANDA for a pharmaceutically equivalent naproxen sodium product, subject to FDA requirements, bioequivalence, manufacturing compliance, and commercial competition.
Is Anaprox a valuable licensing asset?
As a legacy standard tablet, Anaprox has limited licensing value. Any meaningful opportunity would need to arise from a differentiated formulation, dosage form, manufacturing process, or geographic brand right.
References
-
U.S. Food and Drug Administration. (n.d.-a). Naproxen sodium prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-d). Abbreviated new drug application process for generic drugs. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
-
Roche Holding AG. (various years). Annual report. Basel, Switzerland: Roche.
